BIOMAT Database Logo BIOMAT Database Logo

Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura. 1990

M Udvardy, and K Rak

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011697 Purpura, Thrombotic Thrombocytopenic An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases. Moschkowitz Disease,Purpura, Thrombotic Thrombopenic,Thrombotic Thrombocytopenic Purpura, Congenital,Thrombotic Thrombocytopenic Purpura, Familial,Congenital Thrombotic Thrombocytopenic Purpura,Familial Thrombotic Thrombocytopenia Purpura,Familial Thrombotic Thrombocytopenic Purpura,Microangiopathic Hemolytic Anemia, Congenital,Moschcowitz Disease,Schulman-Upshaw Syndrome,Thrombotic Microangiopathy, Familial,Thrombotic Thrombocytopenic Purpura,Upshaw Factor, Deficiency of,Upshaw-Schulman Syndrome,Familial Thrombotic Microangiopathy,Microangiopathy, Familial Thrombotic,Schulman Upshaw Syndrome,Thrombocytopenic Purpura, Thrombotic,Thrombopenic Purpura, Thrombotic,Thrombotic Thrombopenic Purpura,Upshaw Schulman Syndrome
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Udvardy, and K Rak
Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura.
September 1990, Lancet (London, England),
M Udvardy, and K Rak
Does cyclophosphamide benefit relapsing thrombotic thrombocytopenic purpura?
November 2002, The Journal of the Association of Physicians of India,
M Udvardy, and K Rak
Chronic relapsing thrombotic thrombocytopenic purpura.
January 1995, Pediatric hematology and oncology,
M Udvardy, and K Rak
Chronic relapsing thrombotic thrombocytopenic purpura.
April 1987, Southern medical journal,
M Udvardy, and K Rak
Oral cyclophosphamide for refractory or relapsing thrombotic thrombocytopenic purpura (TTP)
August 1997, Australian and New Zealand journal of medicine,
M Udvardy, and K Rak
Treatment of relapsing thrombotic thrombocytopenic purpura with cyclophosphamide pulse therapy.
May 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
M Udvardy, and K Rak
Splenectomy for relapsing thrombotic thrombocytopenic purpura.
June 1997, Annals of internal medicine,
M Udvardy, and K Rak
Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
September 2019, Pediatric nephrology (Berlin, Germany),
M Udvardy, and K Rak
[Three cases of chronic relapsing thrombotic thrombocytopenic purpura].
January 1993, Nihon rinsho. Japanese journal of clinical medicine,
M Udvardy, and K Rak
Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report.
August 2014, Transfusion,
Copied contents to your clipboard!